SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...
Nasdaq

atai Life Sciences Initiates Phase 2 Study of EMP-01 for Social Anxiety Disorder

atai Life Sciences announces Phase 2 study of EMP-01 for social anxiety disorder, with results expected in Q1 2026. atai Life Sciences has announced the dosing of the first patient in a Phase 2 study ...
Cantech Letter

ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

Early Data Suggests a Trend Toward Improvement in Pain Efficacy SASKATOON, SK, Jan. 8, 2026 /CNW/ – ZYUS Life Sciences ...
Nasdaq

Achieve Life Sciences announces outcome of End-of-Phase 2 meeting with FDA

Achieve Life Sciences (ACHV) announced the outcome of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This meeting represents a key milestone in advancing cytisinicline’s ...
Seeking Alpha

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML ...
Business Wire

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated ...
TipRanks on MSN

Sellas Life Sciences says REGAL trial CRO informs company 72 events occurred

SELLAS Life Sciences (SLS) provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients ...
Yahoo Finance

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
Business Wire

Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held ...
Seeking Alpha

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...
Commercial Observer

Phase 3 Signs Life Sciences Tenant to 20K SF in San Diego

The expanding life sciences cluster in Downtown San Diego nabbed a new lab lease, according to the brokerage that represented the landlord. “We believe that being located in Downtown San Diego near ...